{"disease":{"id":"nonalcoholic-fatty-liver-disease-nafld","name":"nonalcoholic fatty liver disease nafld"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"pf-05221304","indication_name":"Nonalcoholic fatty liver disease (NAFLD)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-05221304","generic_name":"pf-05221304","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Acetyl-CoA carboxylase (ACC1 and ACC2)","drug_class":"Acetyl-CoA carboxylase inhibitor","quality_score":27,"revenue":null,"mechanism":"Selective inhibitor of acetyl-CoA carboxylase (ACC1/ACC2) that reduces hepatic lipogenesis and promotes fatty acid oxidation."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03525769","title":"Screening With FibroTouch for Advanced Liver Fibrosis in NAFLD Patients With Underlying Type 2 Diabetes","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT02781584","title":"Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT03486899","title":"A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":197,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT03486912","title":"A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":155,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT02217345","title":"Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"Massachusetts General Hospital","has_results":true},{"nct_id":"NCT03459079","title":"Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"University of Florida","has_results":true},{"nct_id":"NCT03572465","title":"Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis","phase":"","overall_status":"RECRUITING","enrollment_count":102,"lead_sponsor_name":"Centre hospitalier de l'Université de Montréal (CHUM)","has_results":false},{"nct_id":"NCT07278128","title":"Evaluation of the Therapeutic Effects of Curcumin on Changes in Lipid, Metabolic, and Hormonal Profiles, Liver Enzyme Activity, and Ultrasonography Morphology of the Liver in Women With Polycystic Ovary Syndrome and Nonalcoholic Fatty Liver Disease: A Double-blind, Placebo-controlled Clinical Trial","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Fateme Moshirenia","has_results":false},{"nct_id":"NCT02196831","title":"Tesamorelin Effects on Liver Fat and Histology in HIV","phase":"NA","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Massachusetts General Hospital","has_results":true},{"nct_id":"NCT07093346","title":"The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","phase":"NA","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"University of Nottingham","has_results":false},{"nct_id":"NCT03042767","title":"Anti-LPS Antibody Treatment for Pediatric NAFLD","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Miriam Vos, MD","has_results":true},{"nct_id":"NCT03836443","title":"Postprandial Lipotoxicity and Nonalcoholic Fatty Liver Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06024408","title":"A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT04371653","title":"A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally in Subjects With Nonalcoholic Fatty Liver Disease","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"The University of Texas Health Science Center, Houston","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}